Completed PHASE2 INTERVENTIONAL NCT00315276

Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

A 9-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With Attention Deficit/Hyperactivity Disorder

Sponsor: Cephalon

Conditions ADHD Attention Deficit Hyperactivity Disorder

Interventions Modafinil

Updated 6 times since 2017 Last updated: Aug 22, 2012 Started: May 31, 2006 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates ADHD and Attention Deficit Hyperactivity Disorder and is currently completed. Cephalon leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jan 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cephalon

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cambridge, United States , Charleston, United States , Chicago, United States , Clementon, United States , Lafayette, United States , Lexington, United States , Little Rock, United States , Lutherville, United States , Memphis, United States , New York, United States and 8 more locations